The role of downregulation of insulin receptor substrate 1 in the invasion and metastasis of head and neck squamous cell carcinoma

Abstract

Abstract: AIM: To explore the role of insulin receptor substrate 1 (IRS-1) in the invasion and metastasis of head and neck squamous cell carcinoma(HNSCC) and potential mechanism. METHODS: IRS-1 mRNA expression in the metastatic lymph node and corresponding primary tumour tissues of HNSCC patients, in highly and poorly metastatic HNSCC cells were detec-ted byqRT-PCR. miR-9 and U6 expression were measured by the TaqMan microRNA qPCR. IRS-1 expression was downregulated by using siRNA. The effect of IRS-1 on cell invasive potency was examined by transwell invasion assay after IRS-1 interference. E-cadherin and vimentin were detected by qRT-PCR and Western blot. Cell survival rate was examined by SRB assay. RESULTS: IRS-1 mRNA expression decreased in the metastatic lymph node tumor tissues compared to primary tumor tissues of HNSCC patients(P<0.05). As well, its expression levels were lower in highly metastatic HNSCC cells compared to its parental poorly metastatic cells(P<0.05). IRS-1 knockdown promoted invasion of poorly metastatic 686LN cells and induced EMT in parallel with upregulation of miR-9 expression. CONCLUSION: Downregulation of IRS-1 may promote invasion and metastasis of head and neck squamous cell carcinoma by epithelial-mesenchymal transition and upregulating miR-9 expression.

Key words: Insulin receptor substrate 1 (IRS-1), Head and neck squamous cell carcinoma (HNSCC), Metastasis, E-cadherin, miR-9

CLC Number:

LUO Xuan, HUANG Wen-bin, ZHAI Su-lan, MA Zhuo, LI Ping, WANG Xue-rong. The role of downregulation of insulin receptor substrate 1 in the invasion and metastasis of head and neck squamous cell carcinoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 744-749.

References

[1] Jemal A, Siegel R, Xu J, et al. Cancer statistics [J]. CA Cancer J Clin, 2010, 60(5): 277- 300.
[2] Muller S, Su L, Tighiouart M, et al. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation [J]. Cancer, 2008, 113(1): 97- 107.
[3] Dearth RK, Cui X, Kim HJ, et al. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2 [J]. Cell Cycle, 2007, 6(6): 705- 713.
[4] Metz HE, Houghton AM. Insulin receptor substrate regulation of phosphoinositide 3-kinase [J]. Clin Cancer Res, 2011, 17(2): 206- 211.
[5] Chang Q, Li Y, White MF, et al. Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications[J]. Cancer Res, 2002, 62(21): 6035- 6038.
[6] Shi J, Wang DM, Wang CM, et al. Insulin receptor substrate-1 suppresses transforming growth factor-beta1-mediated epithelial-mesenchymal transition [J]. Cancer Res, 2009, 69(18): 7180- 7187.
[7] 邵志凌, 何学心, 向谨逸. 尾加压素Ⅱ诱导心肌细胞肥大及对ERK/NF-κB通路的影响[J]. 医药导报, 2011, 30(5) : 566- 569.
[8] Cantarini MC, de la Monte SM, Pang M, et al. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms [J]. Hepatology, 2006, 44(2): 446- 457.
[9] Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 [J]. Nat Cell Biol, 2008, 10(5): 593- 601.
[10] Tiede S, Kloepper JE, Ernst N, et al. Nestin in human skin: exclusive expression in intramesenchymal skin compartments and regulation by leptin [J]. J Invest Dermatol, 2009, 129(11): 2711- 2720.
[11] Dubrovska A, Kim S, Salamone RJ, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations [J]. Proc Natl Acad Sci U S A, 2009, 106(1): 268- 273.
[12] Ma Z, Gibson SL, Byrne MA, et al. Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis [J]. Mol Cell Biol, 2006, 26(24): 9338- 9351.
[13] Gibson SL, Ma Z, Shaw LM. Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis [J]. Cell Cycle, 2007, 6(6): 631- 637.
[14] Houghton AM, Rzymkiewicz DM, Ji H, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth [J]. Nat Med, 2010, 16(2): 219- 223.
[15] Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing [J]. Cell, 2008, 132(1): 9- 14.
[16] Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way [J]. Cell, 2009, 136(4): 586- 591.
[17] 龚志成, 黄琼, 刘昭前. miRNA在糖尿病中的研究进展[J]. 中国临床药理学与治疗学, 2010, 15( 2): 214- 218.
[18] Nicoloso MS, Spizzo R, Shimizu M. MicroRNAs-the micro steering wheel of tumour metastases [J]. Nat Rev Cancer, 2009, 9(4): 293- 302.
[19] Myatt SS, Wang J, Monteiro LJ, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer [J]. Cancer Res, 2010, 70(1): 367- 377.
[20] Rotkrua P, Akiyama Y, Hashimoto Y, et al. MiR-9 downregulates CDX2 expression in gastric cancer cells [J]. Int J Cancer, 2011, 129(11): 2611- 2620.
[21] Ma L, Young J, Prabhala H, et al. MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis [J]. Nat Cell Biol. 2010, 12(3): 247- 256.